ALEMS Fundamental Analysis - EUROPEAN MEDICAL SOLUTIONS S

Fundamental Rating

ALEMS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 70 industry peers in the Biotechnology industry. While ALEMS is still in line with the averages on profitability rating, there are concerns on its financial health. ALEMS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALEMS was profitable.

In the past year ALEMS had a positive cash flow from operations.

ALEMS had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALEMS reported negative operating cash flow in multiple years.

1.2 Ratios

ALEMS's Return On Assets of 1.13% is fine compared to the rest of the industry. ALEMS outperforms 75.71% of its industry peers.

The Return On Equity of ALEMS (5.28%) is better than 81.43% of its industry peers.

Looking at the Return On Invested Capital, with a value of 3.04%, ALEMS is in the better half of the industry, outperforming 80.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	1.13%
ROE	5.28%
ROIC	3.04%

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 1.21%, ALEMS is in the better half of the industry, outperforming 75.71% of the companies in the same industry.

The Operating Margin of ALEMS (2.78%) is better than 78.57% of its industry peers.

In the last couple of years the Operating Margin of ALEMS has grown nicely.

Looking at the Gross Margin, with a value of 20.13%, ALEMS is in line with its industry, outperforming 51.43% of the companies in the same industry.

ALEMS's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	2.78%
PM (TTM)	1.21%
GM	20.13%

OM growth 3Y226.24%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.83%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALEMS is destroying value.

ALEMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ALEMS has an Altman-Z score of -1.11. This is a bad value and indicates that ALEMS is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -1.11, ALEMS perfoms like the industry average, outperforming 45.71% of the companies in the same industry.

A Debt/Equity ratio of 1.45 is on the high side and indicates that ALEMS has dependencies on debt financing.

The Debt to Equity ratio of ALEMS (1.45) is worse than 62.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.45
Debt/FCF	N/A
Altman-Z	-1.11

ROIC/WACC0.39

WACC7.85%

2.3 Liquidity

ALEMS has a Current Ratio of 1.53. This is a normal value and indicates that ALEMS is financially healthy and should not expect problems in meeting its short term obligations.

ALEMS's Current ratio of 1.53 is on the low side compared to the rest of the industry. ALEMS is outperformed by 62.86% of its industry peers.

A Quick Ratio of 0.95 indicates that ALEMS may have some problems paying its short term obligations.

ALEMS's Quick ratio of 0.95 is on the low side compared to the rest of the industry. ALEMS is outperformed by 72.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.53
Quick Ratio	0.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.44% over the past year.

Looking at the last year, ALEMS shows a quite strong growth in Revenue. The Revenue has grown by 11.26% in the last year.

Measured over the past years, ALEMS shows a small growth in Revenue. The Revenue has been growing by 7.56% on average per year.

EPS 1Y (TTM)43.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%154.38%

Revenue 1Y (TTM)11.26%

Revenue growth 3Y7.56%

Revenue growth 5YN/A

Sales Q2Q%17.78%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 35.77 indicates a quite expensive valuation of ALEMS.

Compared to the rest of the industry, the Price/Earnings ratio of ALEMS indicates a rather cheap valuation: ALEMS is cheaper than 82.86% of the companies listed in the same industry.

ALEMS is valuated rather expensively when we compare the Price/Earnings ratio to 27.06, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	35.77
Fwd PE	N/A

4.2 Price Multiples

90.00% of the companies in the same industry are more expensive than ALEMS, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	8.72

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALEMS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUROPEAN MEDICAL SOLUTIONS S

EBR:ALEMS (9/5/2025, 7:00:00 PM)

4.6495

+0.3 (+6.89%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-24 2025-07-24

Earnings (Next)10-15 2025-10-15

Inst Owners0.02%

Inst Owner ChangeN/A

Ins Owners1.2%

Ins Owner ChangeN/A

Market Cap19.67M

Analysts34.29

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	35.77
Fwd PE	N/A
P/S	0.44
P/FCF	N/A
P/OCF	7.69
P/B	1.9
P/tB	25.25
EV/EBITDA	8.72

EPS(TTM)0.13

EY2.8%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.24

FCFYN/A

OCF(TTM)0.6

OCFY13%

SpS10.67

BVpS2.44

TBVpS0.18

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	1.13%
ROE	5.28%
ROCE	4.8%
ROIC	3.04%
ROICexc	3.69%
ROICexgc	6.01%
OM	2.78%
PM (TTM)	1.21%
GM	20.13%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y226.24%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.83%

GM growth 5YN/A

F-Score7

Asset Turnover0.93

Health

		Industry Rank	Sector Rank
Debt/Equity	1.45
Debt/FCF	N/A
Debt/EBITDA	4.56
Cap/Depr	174.79%
Cap/Sales	7.91%
Interest Coverage	1.83
Cash Conversion	77.55%
Profit Quality	N/A
Current Ratio	1.53
Quick Ratio	0.95
Altman-Z	-1.11

F-Score7

WACC7.85%

ROIC/WACC0.39

Cap/Depr(3y)97.27%

Cap/Depr(5y)N/A

Cap/Sales(3y)6.88%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%154.38%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)11.26%

Revenue growth 3Y7.56%

Revenue growth 5YN/A

Sales Q2Q%17.78%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y1021.32%

EBIT growth 3Y250.9%

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y76.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y255.38%

OCF growth 3Y94.38%

OCF growth 5YN/A

EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens